FDA Approves Modular PMA Pathway for FemBloc, Clearing Key Hurdle
FEMY is trading near its 52-week low of $2.022 (6.3% above the low).
Summary
Femasys received FDA approval for a modular PMA submission approach for FemBloc, its non-surgical permanent birth control device. This is a major regulatory milestone that de-risks the path to U.S. approval. The company also announced FemBloc is approved for marketing in Europe and select international markets, opening near-term revenue opportunities. This follows a $30M private placement at $3.20 per share and recent patent grants for the device's polymer component. With a market cap of only $18M and cash of $1.4M at quarter end, the regulatory progress is critical for the company's viability. The modular approach allows Femasys to submit PMA modules sequentially, potentially accelerating the review timeline.
At the time of this announcement, FEMY was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.4M. The 52-week trading range was $2.02 to $22.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.